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Alzheimer’s disease (AD) is an epidemiologically complex
disorder, in which both genetic and environmental factors
play important roles contributing to disease susceptibility.
Identiﬁcation of these risk factors is crucial as they may
provide new avenues for the identiﬁcation of novel dis-
ease biomarkers as well as for the design of intervention
approaches. Several novel AD susceptibility genes with small
risk eﬀects have been recently identiﬁed by employing
genetic association analyses, in particular by those using a
genome-wide approach. For most of the newly identiﬁed
AD risk factors, however, the biological mechanisms driving
these associations remain elusive, emphasizing the need for
comprehensive functional characterization of these genes
and for determining their relevance for AD pathogenesis. In
addition, epidemiological and clinical studies have revealed
that certain comorbidities often precede or cooccur with
AD. These are often correlated with modiﬁable life-style
factors potentially providing promising alternative routes to
be exploited in treatment studies. For this special issue of
the International Journal of Alzheimer’s Disease,w ei n v i t e d
investigators to contribute original research and review
articles that stimulate eﬀorts to identify novel molecular
targets involved in AD pathogenesis. Eventually, we selected
to include eight articles on the topic, which we believe to be
of particular interest to the readers of the journal.
The ﬁrst set of four studies in this special issue elucidates
an u m b e ro fd i ﬀerent genetic aspects of AD. The study by
G. Hamilton et al. assessed the impact of recently identiﬁed
AD genome-wide association signals on cognitive function-
ing in two birth cohorts from Scotland. Their strongest
results implicate a haplotype at the TRAPPC6A locus in
individuals lacking the APOEε4 allele. Less-pronounced
eﬀects on cognition are also observed for genetic variants
in APP and BIN1. The study by L. Polito et al. investigated
the potential role of SLC6A4, a serotonin transporter highly
expressed in the brain, in contributing to AD risk. While
they found nominally signiﬁcant risk eﬀects in their own
case-control sample from Italy, combining these data with
those from other groups yields a more ambiguous answer.
The study by R. Dominici et al. followed a similar approach
investigating the potential eﬀects of DNA sequence variants
in G protein-coupled receptor 3 (GPR3) in AD cases and
controls from Italy. In agreement with recent genome-wide
association studies, they found no evidence that GPR3 is
involved in AD epidemiology. Finally,the paper by E. Blom
et al. chose a more functionally orientated approach to
AD genetics. The authors performed a genome-wide gene
expression study in transgenic mouse models of AD, which
suggested diﬀerences in expression patterns in genes of
the Wnt pathway. Validation experiments in human brain
samples conﬁrm these ﬁndings and suggest that TCF7L2 and
MYC show the largest expression diﬀerences in AD versus
control subjects.
The second set of studies focus on comorbidities and
life-style factors that are associated with AD. In the paper
by V. Leinonen et al., investigators assessed the well-known
AD-related biomarkers, such as Aβ42, tau protein, and
inﬂammatory components from the cerebrospinal ﬂuid
samples obtained from the patients of idiopathic normal
pressure hydrocephalus (iNPH). As AD is the most impor-
tant diﬀerential diagnosis for iNPH, brain biopsy samples
obtained from NPH patients provide valuable information2 International Journal of Alzheimer’s Disease
on pathogenic events taking place in early phase of AD. The
paper by G. Pasinetti et al. summarizes the eﬀects of caloric
intake, dietary life-style and macronutrient composition
on the risk of AD. More speciﬁcally, the investigators
discuss how certain cardiovascular and diabetic conditions
can induce an increased susceptibility for AD and provide
potentialmechanisms through which this may occur. The
paper by E. Tuminello et al. provides a comprehensive
reviewrelatedtothehypothesisofapolipoproteinE(protein:
apoE; gene: APOE) antagonistic pleiotropy. The leading
hypothesis is that the APOEε4 allele may be beneﬁcial in
earlier ages, while it leads to cognitive decline later in life.
Finally, the last paper by V. Leduc et al. highlights the
pleiotropic roles and the structure-function relationship of
apoE particularly in the lipid homeostasis-related events in
AD and cardiovascular diseases.
Taken together, we believe that the articles included in
this special issue of the International Journal of Alzheimer’s
Disease shed new light on a number of diﬀerent aspects
of AD pathogenesis. In concert with the work from hun-
dreds of other AD laboratories worldwide, these exciting
new data will hopefully translate into the identiﬁcation of
novel biomarkers and the development of new therapeutic
strategies to eﬃciently diagnose and treat this devastating
disorder.
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